XBiotech Inc. (XBIT)
Stock Price:
$18.12 USD
-0.19 (-1.04%)
Updated Oct 26, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
525.28M |
| Revenue (ttm) |
28.18M |
| Net Income (ttm) |
673.49M |
| Shares Out |
28.99M |
| EPS (ttm) |
15.24 |
| PE Ratio |
1.19 |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 26, 2020 |
| Last Price |
$18.12 |
| Previous Close |
$18.31 |
| Change ($) |
-0.19 |
| Change (%) |
-1.04% |
| Day's Open |
18.16 |
| Day's Range |
17.76 - 18.65 |
| Day's Volume |
107,756 |
| 52-Week Range |
8.72 - 26.40 |
More Stats
| Market Cap |
525.28M |
| Enterprise Value |
295.58M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
28.99M |
| Float |
14.49M |
| EPS (basic) |
17.25 |
| EPS (diluted) |
15.24 |
| FCF / Share |
-2.84 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
84.11% |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.77M |
| Short Ratio |
10.51 |
| Short % of Float |
12.20% |
| Beta |
1.50 |
| PE Ratio |
1.19 |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
18.64 |
| PB Ratio |
1.53 |
| Revenue |
28.18M |
| Operating Income |
-28.11M |
| Net Income |
673.49M |
| Free Cash Flow |
-81.95M |
| Net Cash |
229.70M |
| Net Cash / Share |
7.92 |
| Gross Margin |
18.80% |
| Operating Margin |
-99.74% |
| Profit Margin |
2,390.00% |
| FCF Margin |
-290.83% |
| ROA |
-8.16% |
| ROE |
326.16% |
| ROIC |
1,004.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
18.0
Current: $18.12
High
18.0
Target: 18.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | - | - | - | - | - | - | - |
| Operating Income | -31.23 | -20.99 | -34.06 | -52.76 | -37.51 | -21.78 | -9.93 | -15.16 |
| Net Income | 669 | -21.14 | -33.15 | -52.76 | -37.48 | -21.72 | -9.93 | -15.16 |
| Shares Outstanding | 38.95 | 35.80 | 34.88 | 32.40 | 30.80 | 24.16 | 22.22 | 21.29 |
| Earnings Per Share | 14.44 | -0.59 | -0.95 | -1.63 | -1.22 | -0.90 | -0.45 | -0.71 |
| Operating Cash Flow | -18.27 | -16.54 | -33.65 | -46.02 | -33.31 | -11.70 | -8.91 | -11.63 |
| Capital Expenditures | -0.20 | -0.12 | -1.41 | -13.91 | -10.39 | -1.40 | -0.06 | -0.55 |
| Free Cash Flow | -18.47 | -16.66 | -35.05 | -59.93 | -43.70 | -13.10 | -8.97 | -12.18 |
| Cash & Equivalents | 715 | 15.82 | 31.77 | 34.32 | 91.05 | 57.33 | 7.24 | - |
| Net Cash / Debt | 715 | 15.82 | 31.77 | 34.32 | 91.05 | 57.33 | 7.24 | - |
| Assets | 817 | 44.35 | 62.97 | 67.05 | 109 | 62.18 | 11.07 | - |
| Liabilities | 61.25 | 2.95 | 2.81 | 7.99 | 6.31 | 3.15 | 0.85 | - |
| Book Value | 756 | 41.40 | 60.16 | 59.06 | 103 | 59.03 | 10.23 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
XBiotech Inc. |
| Country |
United States |
| Employees |
78 |
| CEO |
John Simard |
Stock Information
| Ticker Symbol |
XBIT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: XBIT |
| IPO Date |
April 15, 2015 |
Description
XBiotech, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. Its product candidates include 514G3, an anti-infective antibody that is in Phase II clinical trial for the treatment of Staphylococcus Aureus infections; and other anti-infectious disease antibodies, which are in pre-clinical development to treat Clostridium Difficile, influenza, Ebola, and Herpes Varicella Zoster (Chickenpox). XBiotech Inc. has a collaboration with BioBridge Global for the development of potential COVID 19 treatment based on natural antibodies from recovered patients. The company was founded in 2005 and is headquartered in Austin, Texas.